PODD : Summary for Insulet Corporation - Yahoo Finance

U.S. Markets closed

Insulet Corporation (PODD)


NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
43.41-0.82 (-1.85%)
At close: 4:00PM EDT
People also watch
DXCMNXTMNUVAHTWRWMGI
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
1d
Previous Close44.23
Open44.44
Bid15.53 x 100
Ask0.00 x
Day's Range43.38 - 44.44
52 Week Range26.50 - 48.23
Volume434,841
Avg. Volume456,357
Market Cap2.51B
Beta2.04
PE Ratio (TTM)-86.13
EPS (TTM)N/A
Earnings DateN/A
Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • Capital Cube21 hours ago

    Insulet Corp. – Value Analysis (NASDAQ:PODD) : April 28, 2017

    Categories: Fundamental Analysis Yahoo FinanceClick here to see latest analysis Capitalcube gives Insulet Corp. a score of 44. Our analysis is based on comparing Insulet Corp. with the following peers – Unilife Corporation, ICU Medical, Inc., Delcath Systems, Inc., Tandem Diabetes Care, Inc., DexCom, Inc., Echo Therapeutics, Inc., Eli Lilly and Company, Abbott Laboratories, Johnson & Johnson and Medtronic ... Read more (Read more...)

  • Insulet Corp. breached its 50 day moving average in a Bullish Manner : PODD-US : April 27, 2017
    Capital Cube2 days ago

    Insulet Corp. breached its 50 day moving average in a Bullish Manner : PODD-US : April 27, 2017

    Categories: ETFs Yahoo FinanceClick here to see latest analysis *Disclaimer : This is as of previous day’s closing price. Technical Indicators Below is a quick look at 5 technical indicators for Insulet Corp.. More studies are available on the Technical Chart. Indicator Signal Closing Price above/below 50 Day Moving Average Bullish Closing Price above/below 200 Day Moving Average ... Read more (Read more...)

  • Is Medtronic's Artificial Pancreas the Next Big Thing in Diabetes?
    Motley Fool16 days ago

    Is Medtronic's Artificial Pancreas the Next Big Thing in Diabetes?

    Medtronic's MiniMed 670G could reduce the burden on Type 1 diabetes patients, as well as slow diabetes progression by keeping blood glucose levels on target.